LevinA., BakrisG.L., MolitshM..; Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluateearly kidney disease.Kidney Int2007; 71: 31–8.
2.
MoranneO., FroissartM., RossertJ.. Timing of onset of CKD-related metabolic complications.J Am Soc Nephrol2009; 20: 164–71.
3.
GoodmanW.G., QuarlesL.D.Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics.Kidney Int2008; 74: 276–88.
4.
GaneshS.K., StackA.G., LevinN.W.. Association of elevated serum PO4, Ca xPO4 product, and parathyroid-hormone with cardiac mortality risk in chronic hemodialysis patients.J Am Soc Nephrol2001; 12: 2131–8.
5.
BlockG.A., PortF.K.Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.Am J Kidney Dis2000; 35: 1226–37.
6.
BlockG., PortF.K.Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease.Semin Dial2003; 16: 140–7.
7.
MoeS.M., DrüekeT., LameireN., EknoyanG.Chronic kidney disease-mineral-bone disorder: a new paradigm.Adv Chronic Kidney Dis2007; 14(1Il calciomimetico nell'iperparatiroidismo primitivo e se): 3–12.
8.
National Kidney Foundation: K/DOQI clinical practice guidelines on bone metabolism and disease.Am J Kidney Dis2003; 42 (Suppl 3): S1–201.
9.
YoungE.W., AlbertJ.M., SatayathumS.. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.Kidney Int2005; 67: 1179–87.
10.
BrownE.M.Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messenger.Physiol Rev1991; 71: 371–411.
11.
BrownE.M., GambaG., RiccardiD.. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid.Nature1993; 366: 575–80.
BrownE.M.Calcium receptor and regulation of parathyroid hormone secretion.Rew Endocrine and Metab Dis2000; 1: 307–15.
17.
BaJ., FriedmanP.A.Calcium-sensing receptor regulation of renal mineral ion transport.Cell Calcium2004; 35: 229–37.
18.
GambaG., FriedmanP.A.Thick ascending limb: the Na(+): K (+): 2Cl (-) co-transporter, NKCC2, and the calcium-sensing receptor, CaSR.Pflugers Arch2008 Nov 4. [Epub ahead of print].
19.
DvorakM.M., RiccardiD.Ca(2+) as an extracellular signal in bone.Cell Calcium2004; 35: 249–55.
20.
ChangW., TuC., ChenT.H., BikleD., ShobackD.The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development.Sci Signal2008; 1(35): ra1
21.
BrownE.M., WilsonR.E., EastmanR.C., PallottaJ., MarynickP.Abnormalregulation of parathyroidhormone release by calcium in secondary hyperparathyroidism due to chronic renal failure.J Clin Endocrinol Metab1982; 54: 172–9.
22.
BrownA.J., RitterC.S., FinchJ.L., SlatopolskyE.A.Decreased calcium-sensing receptor extression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate.Kidney Int1999; 55: 1284–92.
23.
MalbertiF., FainaM., ImbasciatiE.The PTH-calcium curve and the set point of calcium in primary and secondaryhy perparathyroidism.Nephrol Dial Transplant1999; 14: 2398–406.
24.
MessaP., ValloneC., MioniG., GeattiO., TurrinD., PassoniN., CruciattiA.Direct in vivo assessment of parathyroid hormone-calcium relationship curve in renal patients.Kidney Int1994; 46: 1713–20.
25.
NemethE.F., SteffeyM.E., HammerlandL.G.. Calcimimetics with potent and selectiveactivity on the parathyroid calcium receptor.Proc Natl Acad Sci USA1998; 95: 4040–5
26.
GoodmanW.G., FrazaoJ.M., GoodkinD.A.. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.Kidney Int2000; 58: 436–45.
27.
KumarG.N., SproulC., PoppeL.. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models.Drug Metab Dispos2004; 32: 1491–500.
28.
HarrisR.Z., PadhiD., MarburyT.C., NoveckR.J., SalfiM., SullivanJ.T.Pharmacokinetics, pharmacodynamic, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily.Am J Kidney Dis2004; 44: 1070–76.
PadhiD., SalfiM., HarrisR.Z.The pharmacokinetics of Cinacalcet are unaffected following consumption of high- and low-fat meals.Am J Ther2007; 14: 235–40.
31.
LindbergJ.S., CulletonB., WongG.. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.J Am Soc Nephrol2005; 16: 800–07.
32.
SerraA.L., BraunS.C., StarkeA.. Pharmacokinetics and pharmacodynamics of Cinacalcet in patients with hyperparathyroidism after renal transplantation.Am J Transplant2008; 8: 803–10.
33.
EvenepoelP.Calcimimetics in chronic kidney disease: evidence, opportunities and challenges.Kidney Int2008; 74: 265–75.
34.
GoodmanW.G., HladikG.A., TurnerS.A..;: The calcimimetic agent AMG 073 lowers plasma hormone levels in hemodialysis patients with secondary hyperparathyroidism.J Am Soc Nephrol2002; 13: 1017–24.
35.
QuarlesL.D., SherrardD.J., AdlerS.. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.J Am Soc Nephrol2003; 14: 575–83.
36.
LindbergJ.S., MoeS.M., GoodmanW.G.. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.Kidney Int2003; 63: 248–54.
37.
BlockG.A., MartinK.J., de FranciscoA.L.M.. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.New Eng J Med2004; 350: 1516–25.
38.
MoeS.M., CunninghamJ, BommerJ.. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.Nephrol Dial Transplant2005; 20: 2186–93.
39.
StrippoliG.F.M., PalmerS., TongA., ElderG., MessaP., CraigJ.C.Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.Am J Kidney Dis2006; 47: 715–26.
40.
MessaP., MacarioF., YagoobM.. The optima study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.Clin J Am Soc Nephrol2008; 3: 36–45.
41.
BlockG.A., ZeigS., SugiharaJ., ChertowG.M., ChiE.M., TurnerS.A., BushinskyD.A.; TARGET Investigators. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.Nephrol Dial Transplant2008; 23(7): 2311–8.
42.
FishbaneS., ShapiroW.B., CorryD.B.. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.Clin J Am Soc Nephrol2008; 3(6): 1718–25.
43.
CannellaG., MessaP.Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both?J Nephrol2006; 19(4): 399–402.
44.
DrüekeT.B., RitzE.Treatment of secondary hyperparathyroidism n CKD patients with Cinacalcet and /or Vitamin D Derivatives.Clin J Am Soc Nephrol2009; 4: 234–41.
45.
WetmoreJ.B., QuarlesL.D.Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in endstage renal disease: time for a paradigm shift?Nature Clin Pract Nephrol2009; 5: 24–33.
46.
MallucheH.H., Moner-FaugereM.C., WangG.. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.Clin Nephrol2008; 69: 269–77.
47.
LienY.H.H., SilvaA.L., WhittmanD.Effects of Cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.Nephrol Dial Transplant2005; 20: 1232–7.
CunninghamJ., DaneseM., OlsonK., KlassenP., ChertowG.M.Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.Kidney Int2005; 68: 1793–800.
50.
CollotonM., ShatzenE., MillerG.. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.Kidney Int2005; 67: 467–76.
51.
MeolaM., PetrucciI., BarsottiG.Long-term treatment with cinacalcet and conventional therapy reduces parathyroidhyperplasia in severe secondary hyperparathyroidism.Nephrol Dial Transplant2009; 24(3): 982–9.
52.
KawataT., NaganoN., ObiM.. Cinacalcet suppresses calcification of the aorta and heart in uremic rats.Kidney Int2008; 74: 1270–7.
53.
IvanovskiO., NikolovI.G., JokiN.. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apo-/-)mice.Atherosclerosis2009; I n press.
54.
LopezJ., MendozaF.J., Agulera-TejeroE.. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats.Kidney Int2008; 73: 300–07.
55.
MessaP., AlbertiL., ComoG.. Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients.Nephrol Dial Transplant2007; 22: 2724–5.
56.
ChertowG.M., PupimL.B., BlockG.A.. Evaluation of Cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview.Clin J Am Soc Nephrol2007; 2: 898–905.
57.
CharytanC., CoburnJ.W., ChoncholM.. Cinacalcethydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.Am J Kidney Dis2005; 46: 58–67.
58.
KestenbaumB., SampsonJ.N., RudserK.D.. Serum phosphate levels and mortality risk among people with chronic kidney disease.J Am Soc Nephrol2005; 16: 520–8.
59.
De FranciscoA.L.M., PineraC., PalomarR.Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3–4 chronic kidney disease.Nat Clin Pract online pub 27 May 2008.
60.
CoyneD.W.Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3–4 chronic kidney disease.Nat Clin Pract online pub 13 May 2008.
EvenepoelP., ClaesK., KuypersD.. Natural history-of parathyroid function and calcium metabolism after kidney transplantation: a single centre study.Nephrol Dial Transplant2004; 19: 1281–1287.
63.
GwinnerW., SuppaS., MengelM.. Early calcification of renal allografts detectedby protocol biopsies: causes and clinical implications.Am J Transplant2005; 5: 1934–41.
64.
SzwarcI., ArgilésA., GarrigueV., DelmasS., ChongG., DeleuzeS., MouradG.Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism.Transplantation2006; 82: 675–80.
65.
KruseA.E., EisenbergerU., FreyF.J., MohauptM.G.Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism.Nephrol Dial Transplant2007; 22: 2362–5.
66.
SerraA.L., WuhrmannC., WüthrichR.P.Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.Am J Kidney Dis2008; 52(6): 1151–7.
67.
BerguaC., TorregrosaJ.V., FusterD., Gutierrez-DalmauA., OppenheimerF., CampistolJ.M.Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism.Transplantation2008; 86: 413–7.
68.
FalckP., VetheN.T., AsbergA., MidtvedtK., BerganS., ReubsaetJ.L., HoldaasH.Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.Nephrol Dial Transplant2008; 23: 1048–53.
